Skip to main content
SpringerLink
Log in

Authors’ Response to Yoshihiro Noguchi’s Comment on: “A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 12 October 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Noguchi Y. Comment on: A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). Drug Saf. 2022. https://doi.org/10.1007/s40264-022-01240-w

    Article  PubMed  Google Scholar 

  2. Villa-Zapata L, Gómez-Lumbreras A, Horn J, et al. A Disproportionality analysis of drug-drug interactions of tizanidine and CYP1A2 inhibitors from the fda adverse event reporting system (FAERS). Drug Saf. 2022;45:863–71.

    Article  CAS  PubMed  Google Scholar 

  3. FDA label. ZANAFLEX Capsules® (tizanidine hydrochloride). 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021447s011_020397s026lbl.pdf. Accessed 31 Aug 2022.

  4. Rudolph A, Dahmke H, Kupferschmidt H, et al. Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database. Eur J Clin Pharmcol. 2021;77:6–13.

    Article  Google Scholar 

  5. Chaugai S, Dickson AL, Shuey MM, et al. Co-prescription of strong CYP1A2 inhibitors and the risk of tizanidine-associated hypotension: a retrospective cohort study. Clin Pharmacol Ther. 2019;105:703–9.

    Article  CAS  PubMed  Google Scholar 

  6. Jödicke AM, Curkovic I, Zellweger U, et al. Analysis of drug-drug interactions in swiss claims data using tizanidine and ciprofloxacin as a prototypical contraindicated combination. Ann Pharmacother. 2018;52:983–91.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kim HR, Sung M, Park JA, et al. Analyzing adverse drug reaction using statistical and machine learning methods: a systematic review. Medicine. 2022;101: e29387.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Norén GN, Sundberg R, Bate A, et al. A statistical methodology for drug–drug interaction surveillance. Stat Med. 2008;27:3057–70.

    Article  PubMed  Google Scholar 

  9. Hult S, Sartori D, Bergvall T, et al. A feasibility study of drug-drug interaction signal detection in regular pharmacovigilance. Drug Saf. 2020;43:775–85.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57–69.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA

    Daniel C. Malone, Ainhoa Gómez-Lumbreras & Malinda S. Tan

  2. Department of Pharmacy Practice, College of Pharmacy, Mercer University, Atlanta, GA, USA

    Lorenzo Villa-Zapata

  3. Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA

    John Horn

  4. Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA

    Richard D. Boyce

Authors
  1. Daniel C. Malone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenzo Villa-Zapata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ainhoa Gómez-Lumbreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Malinda S. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Richard D. Boyce
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel C. Malone.

Ethics declarations

Funding

This research was funded by the Agency for Healthcare Research and Quality, grant number R01HS025984.

Conflicts of interest/Competing interests

The authors declare no conflicts of interest.

Ethics approval

Ethics approval from the IRB was not sought as the study only involved the analysis of data obtained from a public database. Informed consent to participate was not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material (data transparency)

FAERS data is publicly available at: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard

Code availability (software application or custom code)

Not applicable.

Authors' contributions

All authors contributed to the preparation of the letter and read and approved the final version.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malone, D.C., Villa-Zapata, L., Gómez-Lumbreras, A. et al. Authors’ Response to Yoshihiro Noguchi’s Comment on: “A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)”. Drug Saf 45, 1553–1555 (2022). https://doi.org/10.1007/s40264-022-01239-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-022-01239-3

Search

Navigation